Sanjivani Paranteral and HAL Ink Partnership To Produce IV formulations

By: India Pharma Outlook Team | Thursday, 23 November 2023

 India Pharma Outlook Team

Sanjivani Paranteral Limited, a prominent pharmaceutical firm specializing in the production and sale of high-quality parenteral and oral solid products, has entered into a substantial deal with Hindustan Antibiotics Limited for the production of IV formulations and IV Sets. Hindustan Antibiotics Limited has confirmed a purchase commitment under the arrangement.

The partnership will see the establishment of a cutting-edge manufacturing facility within the premises of Hindustan Antibiotics Limited at Pimpri works, Pune, Maharashtra. Sanjivani Paranteral will soon initiate the process of upgrading facilities, the production is likely to start from Q3FY25. The plant capacity will be 50 lakh IV fluids bottles and 10 lakh IV sets per month, as per pharmabiz  

"Our aim is to build a world-class organization grounded in Passion, Performance, and Partnership," said Ashwani Khemka, chairman & managing director of Sanjivani Paranteral Ltd. "Our collaboration with Hindustan Antibiotics Limited not only reaffirms our commitment to innovation and healthcare quality but also aligns with our vision for advancing pharmaceutical manufacturing in India. We believe that by contributing to 'Make in India,' we can significantly impact the evolution of IV formulations and IV Sets, ultimately benefiting patients and healthcare providers."  

Speaking on the partnership, Milind Palhade from Hindustan Antibiotics Ltd, said, “This partnership epitomizes our commitment to fostering innovation and maintaining high-quality standards in the healthcare sector. We firmly believe that our combined capabilities will make a substantial contribution to the progression. The joint venture will help to elevate the standards of pharmaceutical manufacturing, emphasizing innovation, quality, and accessibility in the production of IV formulations and IV Sets. Both the companies are positive about the transformative impact this collaboration will have on healthcare delivery in India.”

© 2024 India Pharma Outlook. All Rights Reserved.